TRANSPLANTATION OF MULTIPOTENT PROGENITOR CELLS IN STROKE

中风患者多能祖细胞的移植

• 批准号: 7940916
• 负责人: CESARIO V BORLONGAN
• 金额: --
• 依托单位: UNIVERSITY OF SOUTH FLORIDA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-08-01 至 2011-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7940916
• 关键词: TRANSPLANTATION; MULTIPOTENT; PROGENITOR; CELLS; STROKE

DESCRIPTION (provided by applicant): Multipotent progenitor cells (MFCs) (Nature, 418:41-49, 2002), developed by Dr. Verfaillie and co- workers at the University of Minnesota, appear to have the properties which make them highly suitable as a stem cell therapy. Athersys, Inc. has the proprietary rights to these cells. We have recently developed a collaborative relationship with Athersys, Inc. which has developed manufacturing techniques to make these cells available for clinical use. Athersys, Inc. will supply these cells to us. Our preliminary data in rodents indicate that these cells are quite promising as a therapy for stroke. In order to develop the utility of these cells in stroke, we propose a translational protocol. The proposed set of experiments will serve as the preclinical basis for proceeding with transplantation of MFCs in ischemic stroke patients. Feasibility, safety, and optimal MFC dose and transplantation timing post- stroke for producing efficacy in rodent models of adult ischemic stroke will be examined. The following specific aims will serve as milestones, with "go and no-go" criteria. Specific Aim 1: Determine the "long-term" (i.e., 6 months post-transplantation) efficacy of IV rat MPCs in transient middle cerebral artery occlusion model. Specific Aim 2: Evaluate the long-term efficacy of IV human MPCs produced by Athersys, Inc. according to GMP manufacturing protocols in a GLP xenogeneic transient middle cerebral artery occlusion model. Specific Aim 3: Assess the efficacy of IV human MPCs to achieve long-term behavioral benefits in male and female, and adult and aged rats exposed to transient middle cerebral artery occlusion model. Specific Aim 4: Demonstrate the efficacy of IV human MPCs to achieve long-term behavioral benefits in permanent middle cerebral artery ligation model. Specific Aim 5: Characterize stem cell histocompatibility in allogeneic rat MPCs and xenogeneic human MPCs to further provide safety of IV MPCs in rat ischemic stroke model. Specific Aim 6: Conduct IND FDA preparation meetings and assemble documents for filing IND for stem cell therapy in ischemic stroke. This proposal extends our scientific platform for determining the benefit of stem cell therapy in stroke.

描述（由申请人提供）：

项目成果

Nestin overexpression precedes caspase-3 upregulation in rats exposed to controlled cortical impact traumatic brain injury.

• DOI: 10.3727/215517912x639306
• 发表时间: 2012
• 期刊: Cell medicine
• 作者: Kaneko Y;Tajiri N;Yu S;Hayashi T;Stahl CE;Bae E;Mestre H;Franzese N;Rodrigues A Jr;Rodrigues MC;Ishikawa H;Shinozuka K;Hethorn W;Weinbren N;Glover LE;Tan J;Achyuta AH;van Loveren H;Sanberg PR;Shivsankar S;Borlongan CV
• 通讯作者: Borlongan CV

Epidemiological survey-based formulae to approximate incidence and prevalence of neurological disorders in the United States: a meta-analysis.

• DOI: 10.1371/journal.pone.0078490
• 发表时间: 2013
• 期刊: PloS one
• 影响因子: 3.7
• 作者: Borlongan CV;Burns J;Tajiri N;Stahl CE;Weinbren NL;Shojo H;Sanberg PR;Emerich DF;Kaneko Y;van Loveren HR
• 通讯作者: van Loveren HR

Advancing critical care medicine with stem cell therapy and hypothermia for cerebral palsy.

通过干细胞疗法和脑瘫的体温过低来推进重症监护医学。

• DOI: 10.1097/wnr.0000000000000062
• 发表时间: 2013-12-18
• 期刊: Neuroreport
• 影响因子: 1.7
• 作者: Dailey T;Mosley Y;Pabon M;Acosta S;Tajiri N;van Loveren H;Kaneko Y;Borlongan CV
• 通讯作者: Borlongan CV

Stem Cells for Neurovascular Repair in Stroke.

干细胞进行中风中的神经血管修复。

• DOI: 10.4172/2157-7633.s4-004
• 发表时间: 2013-05-01
• 期刊: Journal of stem cell research & therapy
• 作者: Shinozuka K;Dailey T;Tajiri N;Ishikawa H;Kim DW;Pabon M;Acosta S;Kaneko Y;Borlongan CV
• 通讯作者: Borlongan CV

A Step-up Approach for Cell Therapy in Stroke: Translational Hurdles of Bone Marrow-Derived Stem Cells.

中风中细胞疗法的升级方法：骨髓来源的干细胞的翻译障碍。

• DOI: 10.1007/s12975-011-0127-8
• 发表时间: 2012-03
• 期刊: Translational stroke research
• 影响因子: 6.9
• 作者: Glover LE;Tajiri N;Weinbren NL;Ishikawa H;Shinozuka K;Kaneko Y;Watterson DM;Borlongan CV
• 通讯作者: Borlongan CV